clinical trial · NCT04666610
A Study to Evaluate the Efficacy, Safety, and Tolerability of Brivaracetam as Monotherapy in Patients 2 to 25 Years of Age With Childhood Absence Epilepsy or Juvenile Absence Epilepsy
UCB Biopharma SRL·phase3·active not recruiting·n = 153
Childhood Absence EpilepsyJuvenile Absence EpilepsyBrivaracetamPlacebo
brief summary
The purpose of the study is to test the efficacy, safety and tolerability of brivaracetam monotherapy in study participants 2 to 25 years of age inclusive with childhood absence epilepsy (CAE) or juvenile absence epilepsy (JAE).
started
Jul 29, 2021
primary completion
Aug 24, 2026
completion
Aug 24, 2026
last updated
Mar 13, 2026
official title
A Randomized, Dose-Finding and Confirmatory, Double-Blind, Placebo-Controlled, Parallel-Group Multicenter Study With a 2 Stage Adaptive Design and Randomized Withdrawal to Evaluate the Efficacy, Safety, and Tolerability of Brivaracetam as Monotherapy in Patients 2 to 25 Years of Age With Childhood Absence Epilepsy or Juvenile Absence Epilepsy
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol